1.76MMarket Cap
LossP/E TTM
Key Figures
0.311Open
0.311High
602.21KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
9.95%Turnover Ratio
0.308Prev. Close
0.281Low
130.70KTurnover
LossP/E Static
0.59P/B
0.00%Div Yield TTM
-480.65%ROA
3.85052wk High
1.27Volume Ratio
-13.16MNet Profit
6.05MShares
-6.0287EPS TTM
0.79Beta
-1122.83%ROE
0.26152wk Low
9.52%Amplitude
--Gross Margin
1.76MMarket Cap
-5.01Reward/Risk
6.94%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
GT Biopharma Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 106 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
GT Biopharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
GT Biopharma Inc Highlights
StrengthsRisks
GT Biopharma Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Ionis Pharmaceuticals Inc
IONS
25
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
GT Biopharma Inc Info
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
Ticker SymbolGTBP
CompanyGT Biopharma Inc
CEOBreen (Michael)
Websitehttps://www.gtbiopharma.com/
Shareholders
FAQs
What is the current price of GT Biopharma Inc (GTBP)?
The current price of GT Biopharma Inc (GTBP) is 0.29.
What is the symbol of GT Biopharma Inc?
The ticker symbol of GT Biopharma Inc is GTBP.
What is the 52-week high of GT Biopharma Inc?
The 52-week high of GT Biopharma Inc is 3.85.
What is the 52-week low of GT Biopharma Inc?
The 52-week low of GT Biopharma Inc is 0.26.
What is the market capitalization of GT Biopharma Inc?
The market capitalization of GT Biopharma Inc is 1.76M.
Is GT Biopharma Inc (GTBP) currently rated as Buy, Hold, or Sell?
According to analysts, GT Biopharma Inc (GTBP) has an overall rating of Buy, with a price target of 3.00.
What is the Earnings Per Share (EPS TTM) of GT Biopharma Inc (GTBP)?
The Earnings Per Share (EPS TTM) of GT Biopharma Inc (GTBP) is -6.25.
